The 2026 guidelines bring clinically meaningful updates to specific LDL-C targets, risk calculation, earlier intervention strategies, and expanded use of ApoB.
John Bucheit, PharmD, BCACP
Advertisement
Articles by John Bucheit, PharmD, BCACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
2
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
GIRE Combination Shows PFS Benefit in First-Line Metastatic Breast Cancer Treatment, Earning FDA Priority Review
5